Post by Nadica (She/Her) on Dec 10, 2024 2:45:17 GMT
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST) - Posted Dec 5, 2024
Highlights
•Vaccine platform type can influence the occurrence of reactogenic events.
•Evidence comparing reactogenicity of COVID vaccines to other vaccines is limited.
•Compared to MenACWY, mRNA COVID vaccines showed higher reactogenicity.
•Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY.
•Further research is needed to compare COVID and other routinely administered vaccines.
Abstract
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.
Highlights
•Vaccine platform type can influence the occurrence of reactogenic events.
•Evidence comparing reactogenicity of COVID vaccines to other vaccines is limited.
•Compared to MenACWY, mRNA COVID vaccines showed higher reactogenicity.
•Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY.
•Further research is needed to compare COVID and other routinely administered vaccines.
Abstract
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.